Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$532.34K
40.39K shares · 0.0% of portfolio
Korro Bio, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -97.0% over 5Y.
today you would have $27.11▼ -97.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.01 | $38.07 | $47.93 | $192.50 | $256.50 | $1,763.00 | $876.50 | |
| P/S | 18.7x | 18.1x | 157.4x | — | — | 12.8x | 32.6x | 18.7x |
| P/B | 2.3x | 2.2x | 2.2x | 2.3x | — | — | 6.3x | 3.2x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $7.88 | — | 1.4x | — | -95.58% | $152.31M |
| INDPIndaptus Therapeutics, Inc. | $1.14 | — | 13.4x | — | -318.04% | $151.9M |
| TNYATenaya Therapeutics, Inc. | $0.68 | — | 2.2x | — | -121.86% | $152.97M |
| EQEquillium, Inc. | $2.39 |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Company description provided by Yahoo Finance.
| EPS | -$12.48 | -$9.37 | -$53.08 | -$227.42 | -$123.50 | -$41.00 | -$114.50 |
| Profit margin | -601.98% | -1834.48% | -3680.36% | — | — | -601.98% | -71.68% | -64.76% |
| ROE | -47.77% | -227.96% | -52.10% | -47.77% | — | — | -13.77% | -11.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.7x |
| — |
| -58.98% |
| $151.55M |
| CDXSCodexis Inc | $1.38 | — | 3.8x | — | -69.36% | $151.12M |
| OKUROnKure Therapeutics, Inc. | $3.79 | — | 0.9x | — | -46.91% | $153.48M |